Chalcone-inspired rA1 /A2A adenosine receptor ligands: ring closure as an alternative to a reactive substructure.
Chrisna MattheeGisella Terre'BlancheHelena D Janse van RensburgJanine AucampLesetja J LegoabePublished in: Chemical biology & drug design (2021)
Over the past few years, great progress has been made in the development of high-affinity adenosine A1 and/or A2A receptor antagonists - promising agents for the potential treatment of Parkinson's disease. Unfortunately, many of these compounds raise structure-related concerns. The present study investigated the effect of ring closures on the rA1 /A2A affinity of compounds containing a highly reactive α,β-unsaturated carbonyl system, hence providing insight into the potential of heterocycles to address these concerns. A total of twelve heterocyclic compounds were synthesised and evaluated in silico and in vitro. The test compounds performed well upon qualitative assessment of drug-likeness and were generally found to be free from potentially problematic fragments. Most also showed low/weak cytotoxicity. Results from radioligand binding experiments confirm that heterocycles (particularly 2-substituted 3-cyanopyridines) can replace the promiscuous α,β-unsaturated ketone functional group without compromising A1 /A2A affinity. Structure-activity relationships highlighted the importance of hydrogen bonds in binding to the receptors of interest. Compounds 3c (rA1 Ki = 16 nM; rA2A Ki = 65 nM) and 8a (rA1 Ki = 102 nM; rA2A Ki = 37 nM), which both act as A1 antagonists, showed significant dual A1 /A2A affinity and may, therefore, inspire further investigation into heterocycles as potentially safe and potent adenosine receptor antagonists.
Keyphrases
- rheumatoid arthritis
- disease activity
- photodynamic therapy
- ankylosing spondylitis
- neoadjuvant chemotherapy
- interstitial lung disease
- systemic lupus erythematosus
- protein kinase
- systematic review
- molecular docking
- risk assessment
- squamous cell carcinoma
- capillary electrophoresis
- anti inflammatory
- drug induced
- light emitting
- idiopathic pulmonary fibrosis
- electronic health record